Inhibition of KLK8 promotes pulmonary endothelial repair by restoring the VE-cadherin/Akt/FOXM1 pathway

Ying Zhao, Hui Ji, Han Feng, Qingfeng Xu, Hui Zhang, Di Liu, Juan Wei, Dan‐Hong Xu, Lai Jiang, Xin Ni, Pingbo Xu, Yujian Liu, Xiaoyan ZhuJournal of Pharmaceutical Analysis 2024 · DOI

This study, recently published in the context of pulmonary research, identifies the serine protease KLK8 as a critical "molecular brake" that prevents lung tissue from repairing itself during sepsis. By inhibiting KLK8—either through genetic deletion or neutralizing antibodies—the researchers were able to restore a vital cellular repair pathway (VE-cadherin/Akt/FOXM1), significantly reducing vascular leakage and improving survival rates in septic mouse models.

TL;DR

Researchers discovered that the enzyme KLK8 spikes during sepsis, where it acts as "molecular scissors" to chop up structural proteins in the lung's blood vessels. This cleavage shuts down the FOXM1 repair pathway, but blocking KLK8 restores the lung’s ability to heal, offering a promising new therapeutic target for treating acute lung injury.

What Problem Does This Paper Address?

Sepsis is a life-threatening condition where the body’s extreme response to infection leads to organ failure. The lungs are particularly vulnerable; the endothelial cells lining the pulmonary blood vessels become "leaky" (hyperpermeable), leading to edema and Acute Lung Injury (ALI).

While we understand how the initial damage occurs, we know much less about why the lungs often fail to repair this barrier effectively. The authors focused on the tissue kallikrein-related peptidase (KLK) family, known to be involved in blood vessel growth, to see if any members were responsible for stalling endothelial regeneration during the inflammatory storm of sepsis.

Methods

The team employed a multi-level experimental approach:

  • Screening: They measured the mRNA levels of all 15 known mouse KLKs in lung tissues and primary Mouse Lung Vascular Endothelial Cells (MLVECs) treated with LPS (a bacterial toxin).
  • Loss/Gain of Function: They used Adenovirus-mediated overexpression to see if too much KLK8 caused injury and siRNA/Global Knockout mice to see if removing it was protective.
  • Therapeutic Testing: They administered KLK8 neutralizing antibodies to mice in two different sepsis models: LPS-induced endotoxemia and Cecal Ligation and Puncture (CLP), which mimics human peritonitis.
  • Mechanistic Discovery: They used RNA-Seq and Bioinformatic analysis (GSEA and IPA) to identify downstream targets, followed by "rescue" experiments using lentiviral vectors to restore specific proteins like FOXM1 or VE-cadherin.

Datasets

  • Transcriptomic Data: The study generated a new RNA-Seq dataset from KLK8-overexpressed endothelial cells, which has been deposited in the NCBI GEO database (accession number GSE216969).
  • Comparative Screening: The researchers evaluated the expression profiles of the entire 15-member KLK family to isolate KLK8 as the primary driver of injury.

Key Insights and Ideas

  • KLK8 is the "Bad Actor": Out of 15 family members, KLK8 was the most highly induced in septic conditions (approx. 3.5-fold increase). Interestingly, other members like KLK1 and KLK10 actually decreased.
  • Structural-to-Transcriptional Link: The most profound insight is the pathway discovery. KLK8 cleaves the extracellular domain of VE-cadherin (a "glue" protein that holds cells together). This physical break doesn't just cause leaks; it stops the Akt signaling protein from activating FOXM1.
  • FOXM1 as the Master Repairman: FOXM1 is a transcription factor essential for cell division. When KLK8 is active, FOXM1 is suppressed, meaning endothelial cells stop proliferating and cannot replace damaged neighbors.
  • Upstream Targeting is Safer: While directly activating FOXM1 can promote tumor growth, the authors suggest that inhibiting KLK8 is a more targeted way to allow natural repair mechanisms to resume only where they have been pathologically suppressed.

Key Results

  • Mortality: In septic mice, KLK8 deficiency or antibody treatment significantly increased survival rates compared to controls.
  • Vascular Integrity: Blocking KLK8 reduced the leakage of Evans blue dye into the lungs and restored the expression of junction proteins like ZO-1 and CD31.
  • Proliferation: Immunofluorescence showed a significant increase in Ki67+/CD31+ cells (proliferating endothelial cells) in the lungs of mice treated with anti-KLK8 antibodies, proving that repair was actively occurring.
  • Quantitative Injury: Overexpressing KLK8 alone in healthy mice was sufficient to induce a lung injury score of 2.32, mimicking the damage seen in actual sepsis.

Limitations and Future Work

  • Prophylactic vs. Therapeutic: Most antibody experiments in this study involved "prophylactic" administration (given shortly before or at the time of injury). Future studies need to determine if the antibody is effective when given after sepsis symptoms have already fully developed.
  • Human Translation: While the mechanisms were validated in mouse cells, clinical trials will be necessary to see if human KLK8 behaves identically and if the neutralizing antibody is safe for human use.
  • Long-term Effects: The study focused on the acute phase (up to 48 hours). The long-term impact of KLK8 inhibition on chronic lung remodeling remains an open question.

Summary updated

Abstract

Image 1.
BibTeX
@article{zhao2024inhibition,
  author = {Ying Zhao and Hui Ji and Han Feng and Qingfeng Xu and Hui Zhang and Di Liu and Juan Wei and Dan‐Hong Xu and Lai Jiang and Xin Ni and Pingbo Xu and Yujian Liu and Xiaoyan Zhu},
  title = {{Inhibition of KLK8 promotes pulmonary endothelial repair by restoring the VE-cadherin/Akt/FOXM1 pathway}},
  journal = {Journal of Pharmaceutical Analysis},
  year = {2024},
  doi = {10.1016/j.jpha.2024.101153},
}

Loading related content...

Figure